Gabapentin is one of the most frequently prescribed analgesic medications in the United States, commonly used for treating neuropathic pain conditions. While generally thought to have a favorable adverse effect profile, emerging data have implicated gabapentin in cases of respiratory depression and overdose-deaths, especially when combined with opioids and other central nervous system depressants. As a result, a growing number of states have reclassified gabapentin as a Schedule-V controlled substance. However, such regulations may risk varied unintended consequences, such as restricting access to a valuable nonopioid analgesic and potentially facilitating illicit market activity. As such, vulnerable populations, particularly those in rural and low-income areas, may face increased barriers to care. This commentary evaluates the rationale for regulating gabapentin, examines the potential risks associated with such oversight, and suggests a way forward to reduce misuse while maintaining access to gabapentin for patients who genuinely need it.
Javed et al. (Mon,) studied this question.